FDA reviewers: Novartis psoriasis drug secukinumab safe, effective
This article was originally published in Scrip
Executive Summary
The currently available data support a favorable benefit-risk assessment for the use of Novartis' secukinumab as a treatment for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, FDA drug reviewers said.